In the contemporary landscape, the global ban on conducting clinical trials using animals as test subjects poses a significant challenge for pharmaceutical and cosmetic companies seeking to test their drugs. To navigate this obstacle, the use of cell lines for in vivo drug testing has emerged as a potential solution. The cosmetic sector, in particular, remains largely unexplored in this context, presenting a significant opportunity for the application of cell line culture to study toxicological effects before progressing to clinical trials.
The ban on animal testing has compelled industries to explore alternative methods, with cell line culture standing out as a promising avenue. While the initial years of implementing this approach faced challenges related to effectiveness and efficiency, the utilization of cell line culture in the cosmetics sector is poised to benefit the market for immortalized cell lines.
Cell lines serve a wide range of applications, encompassing cell therapy, disease pathology, tissue morphogenesis and engineering, gene and protein expression, regenerative medicine, drug discovery, and tissue engineering. Notably, they have found a newfound role in stem cell and cancer research, addressing the need for more effective models to study cancer mechanisms.
In cancer research, the use of immortalized cell lines proves instrumental in understanding cell morphology through cell alteration. Cell lines cultivated in a culture setting result in enhanced gene expression, leading to modified cell morphology, accelerated proliferation rates, and the development of drug resistance—characteristics that contribute to a more representative cancer tissue model.
The application of cell line culture in cancer research holds the potential to significantly enhance our understanding of cancer biology, eliminate poor drug candidates, and identify new, physiologically relevant targets that might be overlooked in traditional 2D screens. The establishment of a 3D model system within cell line culture has proven effective, saving both time and costs while producing more realistic results. The increasing demand for 3D cell culture is attributed to its heightened effectiveness and efficiency in replicating physiological conditions, making it a preferred choice in various research endeavors.
February 2024
For the first time ever, the revolutionary spontaneously immortalized bovine myoblast cell line known as PROFUSE-B8 has been formally introduced, and it is now available for licensing. In announcing its official debut, ProFuse Technology is glad to share the news. This recent achievement, which marks a significant milestone in the field of farmed meat, has resulted in the introduction of a paradigm shift in the efficient growth of muscle tissue that is rich in protein.
The PROFUSE-B8 cell line, which has been the subject of significant study and testing over the course of a full two-year period, provides cultured meat manufacturers with a solid and robust foundation for the establishment of scalable, repeatable, and cost-competitive production processes. This has been accomplished by testing and researching the cell line over the course of two years. It is important to note that B8 is able to do this without using any method that includes genetic alteration. This ensures that it is in complete accordance with the preferences and consent of customers.
Its revolutionary features are complimented by the fact that, when taken with the PROFUSE-S1 muscle differentiation media supplement, the synthesis of muscle tissue is speed up, which results in increased productivity in a shorter length of time. This is a significant advantage.
ProFuse Technology is 100% committed to advancing the cultured meat business by providing cutting-edge solutions for the production of muscle-related goods. This commitment is steadfast. At the same time, the company is making significant progress toward the development of other muscle production-optimized cell lines that are tailored to the unique requirements of chicken, hog, lamb, and fish for specialized purposes.
According to Dr. Tamar Eigler-Hirsh, Chief Technology Officer and Co-Founder of ProFuse Technology, in a statement, "We are thrilled to introduce PROFUSE-B8 as a transformative solution for the cultivated meat industry." "Our dedication to innovation and productivity is evident in the development of this breakthrough cell line, and we are confident it will shape the future of cell based protein production."
Based on end user, the global market is segmented into pharmaceutical and biopharmaceutical companies, Contract Research Organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical companies segment accounted for a market value of USD 1,323.79 million in 2017.
Immortalized Cell Line Industry Developments
In January 2024,Thermo Fisher Scientific Launched new Gibco™ Advanced DMEM/F12 media optimized for immortalized cell lines, claiming improved growth and performance.
In September2023,Lonza Group AG Announced partnership with CStone Pharmaceuticals to optimize and manufacture immortalized cell lines for CAR-T cell therapy development.
Americas
North America
US
Canada
South America
Europe
Western Europe
Germany
UK
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Asia-Pacific
China
Japan
India
South Korea
Rest of Asia-Pacific
Middle East & Africa
Middle East
Africa
Intended Audience
Research and development (R&D) companies
Government research institutes
Academic institutes and universities
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)